Immunovant Announces Two New Development Programs for Batoclimab

September 7, 2022

https://www.globenewswire.com/news-release/2022/09/07/2511243/0/en/Immunovant-Announces-Two-New-Development-Programs-for-Batoclimab.html

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced plans to develop batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy and Graves’ Disease.

Read more at globenewswire.com

Related news for (IMVT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.